Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)
China · Delayed Price · Currency is CNY 52.90
+2.12 (4.17%)
May 20, 2026, 11:30 AM CST
SHA:603538 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,552 | 1,491 | 1,368 | 1,209 | 1,440 | 1,245 |
Other Revenue | 12.03 | 12.03 | 4.66 | 7.79 | 17.37 | 13.47 |
| 1,564 | 1,503 | 1,373 | 1,216 | 1,457 | 1,258 | |
Revenue Growth (YoY) | 12.82% | 9.49% | 12.85% | -16.51% | 15.80% | 5.43% |
Cost of Revenue | 1,070 | 1,013 | 951.57 | 873.79 | 890.82 | 792.22 |
Gross Profit | 494.71 | 490 | 421.28 | 342.71 | 566.16 | 465.93 |
Selling, General & Admin | 219.04 | 220.04 | 218.15 | 213.97 | 248.85 | 193.53 |
Research & Development | 103.92 | 109.35 | 99.65 | 95.3 | 98.16 | 88.31 |
Other Operating Expenses | 6.61 | 8.27 | 8.88 | 0.95 | 14.46 | 11.49 |
Operating Expenses | 334.64 | 340.88 | 327.81 | 316.34 | 360.77 | 295.99 |
Operating Income | 160.07 | 149.11 | 93.47 | 26.36 | 205.4 | 169.94 |
Interest Expense | -42.16 | -41.83 | -48.27 | -29.06 | -27.45 | -27.08 |
Interest & Investment Income | 22.85 | 18.83 | 7.97 | 24.17 | 195.29 | 29.78 |
Currency Exchange Gain (Loss) | -3.67 | -3.67 | 12.48 | -3.45 | 15.52 | 3.2 |
Other Non Operating Income (Expenses) | -12.02 | -5.78 | -8.5 | -2.92 | -1.78 | 1.13 |
EBT Excluding Unusual Items | 125.08 | 116.66 | 57.15 | 15.1 | 386.99 | 176.97 |
Gain (Loss) on Sale of Investments | -1.1 | 4.04 | 4.84 | -18.33 | -6.24 | -5.23 |
Gain (Loss) on Sale of Assets | -0.03 | -0.14 | 0.18 | -9.34 | -20.31 | -6.17 |
Asset Writedown | 3.38 | -2.78 | -1.26 | - | - | -1.43 |
Other Unusual Items | 10.7 | 12 | 26.05 | 20.53 | 23.73 | 16.16 |
Pretax Income | 138.03 | 129.78 | 86.96 | 7.96 | 384.16 | 180.29 |
Income Tax Expense | 22.63 | 23.66 | 10.91 | -8.22 | 16.44 | 22.22 |
Earnings From Continuing Operations | 115.4 | 106.12 | 76.05 | 16.18 | 367.73 | 158.07 |
Minority Interest in Earnings | -3.23 | -3.89 | -9.24 | -4.6 | -28.87 | -15.54 |
Net Income | 112.17 | 102.23 | 66.81 | 11.59 | 338.86 | 142.53 |
Net Income to Common | 112.17 | 102.23 | 66.81 | 11.59 | 338.86 | 142.53 |
Net Income Growth | 51.61% | 53.02% | 476.63% | -96.58% | 137.75% | -8.62% |
Shares Outstanding (Basic) | 216 | 213 | 216 | 232 | 210 | 210 |
Shares Outstanding (Diluted) | 224 | 218 | 216 | 232 | 227 | 213 |
Shares Change (YoY) | 2.74% | 0.93% | -6.99% | 1.89% | 6.91% | 3.50% |
EPS (Basic) | 0.52 | 0.48 | 0.31 | 0.05 | 1.61 | 0.68 |
EPS (Diluted) | 0.50 | 0.47 | 0.31 | 0.05 | 1.49 | 0.67 |
EPS Growth | 47.57% | 51.61% | 520.00% | -96.64% | 122.39% | -11.70% |
Free Cash Flow | 27.96 | 45.48 | -81.87 | -210.41 | -294.67 | -309.26 |
Free Cash Flow Per Share | 0.13 | 0.21 | -0.38 | -0.91 | -1.30 | -1.45 |
Dividend Per Share | 0.155 | 0.155 | 0.050 | 0.020 | 0.165 | 0.142 |
Dividend Growth | 210.00% | 210.00% | 150.00% | -87.88% | 16.11% | - |
Gross Margin | 31.62% | 32.60% | 30.69% | 28.17% | 38.86% | 37.03% |
Operating Margin | 10.23% | 9.92% | 6.81% | 2.17% | 14.10% | 13.51% |
Profit Margin | 7.17% | 6.80% | 4.87% | 0.95% | 23.26% | 11.33% |
Free Cash Flow Margin | 1.79% | 3.03% | -5.96% | -17.30% | -20.22% | -24.58% |
EBITDA | 292.77 | 281.32 | 223.75 | 139.98 | 303.72 | 268.88 |
EBITDA Margin | 18.72% | 18.72% | 16.30% | 11.51% | 20.85% | 21.37% |
D&A For EBITDA | 132.7 | 132.21 | 130.27 | 113.62 | 98.32 | 98.94 |
EBIT | 160.07 | 149.11 | 93.47 | 26.36 | 205.4 | 169.94 |
EBIT Margin | 10.23% | 9.92% | 6.81% | 2.17% | 14.10% | 13.51% |
Effective Tax Rate | 16.40% | 18.23% | 12.55% | - | 4.28% | 12.33% |
Revenue as Reported | 1,564 | 1,503 | 1,373 | 1,216 | 1,457 | 1,258 |
Advertising Expenses | - | 37.21 | 25.77 | 19 | 21.52 | 9.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.